Article
Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC).
Clinical lung cancer - 1 Jan 2018
Gaut Daria, Sim Myung Shin, Yue Yuguang, Wolf Brian R, Abarca Phillip A, Carroll James M, Goldman Jonathan W, Garon Edward B
Abstract excerpt
BACKGROUND: The secondary T790M mutation accounts for more than 50% of acquired tyrosine kinase inhibitor (TKI) resistance in patients with EGFR-mutated non-small-cell lung cancer (NSCLC). Recent reports suggest this resistance mutation may be more common among patients with longer progression-free survival (PFS) on first-line TKI therapy, but much is still unknown. MATERIALS AND METHODS: Our group collected...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.